Repligen Corporation Common Stock vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $61.01 (market cap $395.75M). The key difference: Repligen Corporation Common Stock is far larger — about 28.1× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 65 Days on average.
| RGEN | SLVO | |
|---|---|---|
Market Cap | $11.14B | $395.75M |
Volume | 1,259,263 | 103,065 |
Sector | Health | Income / Options Overlay |
52-Week High | $194.57 | $107.41 |
52-Week Low | $102.87 | $60.11 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $11.02B | — |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SLVO is trading at $63.37, down 1.17% with bearish technical signals showing 16 sell indicators versus 1 buy. The stock recently crossed below its 50-day moving average of $73.20, indicating weakening momentum. Key support levels cluster around $62-63 while resistance sits at $64-65. Recent news highlights silver price declines affecting the ETN's performance.
The outlook remains cautious with technical indicators signaling bearish momentum and silver market volatility creating headwinds. Investment opportunity exists for contrarian investors if silver prices stabilize, but risks include continued commodity weakness and the ETN's structural complexities requiring careful evaluation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →